Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zager, Jonathan
FOCUS, NCT02678572: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma	Completed	3	102	Europe, US	Melphalan/HDS, Alkeran	Delcath Systems Inc., IQVIA Biotech	Melanoma, Ocular	05/23	08/23
NCT05022901: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma	Active, not recruiting	3	30	US	Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), percutaneous hepatic perfusion, PHP, HEPZATO	Delcath Systems Inc.	Metastatic Ocular Melanoma, Metastatic Uveal Melanoma	03/24	03/24
Neo-DREAM, NCT03567889: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients	Recruiting	3	186	Europe, US	Daromun, Surgery, Adjuvant therapy	Philogen S.p.A.	Melanoma Stage IIIB/C	06/24	06/26
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients	Active, not recruiting	2	17	US	Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation	H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated	Melanoma	06/28	06/28
PV-10-MM-1201, NCT02557321: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma	Active, not recruiting	1/2	50	US	PV-10, Rose Bengal Disodium, Pembrolizumab	Provectus Biopharmaceuticals, Inc.	Melanoma	05/23	04/25
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma	Recruiting	1	30	US	Cemiplimab-Rwlc, Libtayo	H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo	Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma	07/24	07/26
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver	No Longer Available	N/A		US	Melphalan, Percutaneous Hepatic Perfusion	Delcath Systems Inc.	Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma